Featured data at EAN 2025

Johnson&Johnson

European Academy of Neurology

Helsinki, Finland
June 21-24, 2025

Johnson & Johnson sponsored IMAAVY™ (nipocalimab) studies

Abstract Number	Title	Presentation time (EEST)
Indirect Treatment Comparisons		
EPR-301	Comparative efficacy of nipocalimab with other FcRn-blocker therapies in generalized myasthenia gravis	Monday, June 23 ePresentation available from 2:30 PM EEST
HCRU Komodo Study		
EPR-087	Healthcare resource utilization and costs associated with exacerbation or crisis in generalized myasthenia gravis	Saturday, June 21 ePresentation available from 2:30 PM EEST
Ph3 VIVACITY-MG3 Neuro-QoL		
EPO-111	Fatigue assessed by Neuro-QoL in Phase 3 VIVACITY-MG3 trial of nipocalimab vs placebo in generalized myasthenia gravis	Saturday, June 21 ePoster available from 1:18 PM EEST
Ph3 VIVACITY-MG3 Long-term Efficacy		
EPR-307	Analysis of long-term efficacy of nipocalimab in myasthenia gravis: open-label extension of the VIVACITY-MG3 trial	Monday, June 23 ePresentation available from 2:20 PM EEST
Ph3 OLE: Placebo to Nipocalimab Switch		
EPR-305	Efficacy of nipocalimab in open-label extension in patients transitioned from placebo: results from VIVACITY-MG3 trial	Monday, June 23 ePresentation available from 2:10 PM EEST
Ph3 VIVACITY-MG3 Treatment Response Predictors		
EPV-667	Predictors of composite response in MG—based on patient and clinician-reported assessments—in VIVACITY-MG3 Phase 3 trial	Saturday, June 21 12:00 PM EEST
Ph3 VIVACITY-MG3 Ocular Effects		
EPR-306	Efficacy of nipocalimab in adult patients with moderate to severe ocular manifestations of gMG in Phase 3 VIVACITY-MG3	Monday, June 23 ePresentation available from 2:15 PM EEST
Ph3 VIVACITY-MG3 PRO		
EPO-300	Assessment of patient-reported outcomes from the Phase 3 VIVACITY-MG3 study of nipocalimab in gMG	Sunday, June 22 ePoster available from 1:21 PM EEST
Delphi BEYOND Study		
EPO-108	Burden of remaining symptoms and fluctuations of generalized myasthenia gravis on patients' daily lives – BEYOND study	Saturday, June 21 ePoster available from 1:09 PM EEST
NOMINATE Study (CIDP)		
EPO-149	A Delphi panel to identify optimal outcome measures in chronic inflammatory demyelinating polyneuropathy (CIDP)	Saturday, June 21 ePoster available from 1:42 PM EEST
PROTECT Study		
EPR-066	Comprehensive analysis of motor endplate pathology in AChR-Ab-positive myasthenia gravis	Saturday, June 21 ePresentation available from 2:15 PM EEST

IMAAVY® IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMAAVY™?

IMAAVY™ is a prescription medicine that may cause serious side effects, including:
· **Infections** are a common side effect of IMAAVY™ that can be serious. Receiving IMAAVY™ may increase your risk of infection. Tell your healthcare provider right away if you have any of the following infection symptoms:

- fever
- chills
- shivering
- cough
- sore throat
- fever blisters
- burning when you urinate

· **Allergic (hypersensitivity) reactions** may happen during or up to a few weeks after your IMAAVY™ infusion. Get emergency medical help right away if you get any of these symptoms during or after your IMAAVY™ infusion:

- swollen face, lips, mouth, tongue, or throat
- difficulty swallowing or breathing
- itchy rash (hives)
- chest pain or tightness

· **Infusion-related reactions** are possible. Tell your healthcare provider right away if you get any of these symptoms during or a few days after your IMAAVY™ infusion

- headache
- rash
- nausea
- fatigue
- dizziness
- chills
- flu-like symptoms
- redness of skin

Do not receive IMAAVY™ if you have a severe allergic reaction to nipocalimab-aahu or any of the ingredients in IMAAVY™. Reactions have included angioedema and anaphylaxis.

Before using IMAAVY™, tell your healthcare provider about all of your medical conditions, including if you:

- ever had an allergic reaction to IMAAVY™
- have or had any recent infections or symptoms of infection.
- have recently received or are scheduled to receive an immunization (vaccine). People who take IMAAVY™ should not receive live vaccines.
- are pregnant, plan to become pregnant, or are breastfeeding. It is not known whether IMAAVY™ will harm your baby.

Pregnancy Safety Study. There is a pregnancy safety study for IMAAVY™ if IMAAVY™ is given during pregnancy or you become pregnant while receiving IMAAVY™. Your healthcare provider should report IMAAVY™ exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMAAVY™?

IMAAVY™ may cause serious side effects. See "What is the most important information I should know about IMAAVY™?"
The most common side effects of IMAAVY™ include: respiratory tract infection, peripheral edema (swelling in your hands, ankles, or feet), and muscle spasms.

These are not all the possible side effects of IMAAVY™. Call your doctor for medical advice about side effects. **You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.**

Please see the full Prescribing Information and Medication Guide for IMAAVY™ and discuss any questions you have with your doctor.

Dosage Form and Strengths: IMAAVY™ is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.